1
|
Pogoda K, Mannell H, Blodow S, Schneider H, Schubert KM, Qiu J, Schmidt A, Imhof A, Beck H, Tanase LI, Pfeifer A, Pohl U, Kameritsch P. NO Augments Endothelial Reactivity by Reducing Myoendothelial Calcium Signal Spreading: A Novel Role for Cx37 (Connexin 37) and the Protein Tyrosine Phosphatase SHP-2. Arterioscler Thromb Vasc Biol 2017; 37:2280-2290. [PMID: 29025706 DOI: 10.1161/atvbaha.117.309913] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2016] [Accepted: 09/26/2017] [Indexed: 01/31/2023]
Abstract
OBJECTIVE Because of its strategic position between endothelial and smooth muscle cells in microvessels, Cx37 (Connexin 37) plays an important role in myoendothelial gap junctional intercellular communication. We have shown before that NO inhibits gap junctional intercellular communication through gap junctions containing Cx37. However, the underlying mechanism is not yet identified. APPROACH AND RESULTS Using channel-forming Cx37 mutants exhibiting partial deletions or amino acid exchanges in their C-terminal loops, we now show that the phosphorylation state of a tyrosine residue at position 332 (Y332) in the C-terminus of Cx37 controls the gap junction-dependent spread of calcium signals. Mass spectra revealed that NO protects Cx37 from dephosphorylation at Y332 by inhibition of the protein tyrosine phosphatase SHP-2. Functionally, the inhibition of gap junctional intercellular communication by NO decreased the spread of the calcium signal (induced by mechanical stimulation of individual endothelial cells) from endothelial to smooth muscle cells in intact vessels, while, at the same time, augmenting the calcium signal spreading within the endothelium. Consequently, preincubation of small resistance arteries with exogenous NO enhanced the endothelium-dependent dilator response to acetylcholine in spite of a pharmacological blockade of NO-dependent cGMP formation by the soluable guanylyl cyclase inhibitor ODQ (1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one). CONCLUSIONS Our results identify a novel mechanism by which NO can increase the efficacy of calcium, rising vasoactive agonists in the microvascular endothelium.
Collapse
Affiliation(s)
- Kristin Pogoda
- From the Walter Brendel Centre of Experimental Medicine, University Hospital, Biomedical Center, Munich, Germany (K.P., H.M., S.B., H.S., K.M.S., J.Q., H.B., L.I.T., U.P., P.K.); Protein Analysis Unit, Biomedical Center, Munich, Germany (A.S., A.I.); DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Germany (K.P., H.M., S.B., H.S., K.M.S., J.Q., H.B., U.P., P.K.); Munich Cluster for Systems Neurology (SyNergY), Germany (A.I., U.P.); and Institute of Pharmacology and Toxicology, Rheinische Friedrich-Wilhelms-Universität Bonn, Germany (A.P.)
| | - Hanna Mannell
- From the Walter Brendel Centre of Experimental Medicine, University Hospital, Biomedical Center, Munich, Germany (K.P., H.M., S.B., H.S., K.M.S., J.Q., H.B., L.I.T., U.P., P.K.); Protein Analysis Unit, Biomedical Center, Munich, Germany (A.S., A.I.); DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Germany (K.P., H.M., S.B., H.S., K.M.S., J.Q., H.B., U.P., P.K.); Munich Cluster for Systems Neurology (SyNergY), Germany (A.I., U.P.); and Institute of Pharmacology and Toxicology, Rheinische Friedrich-Wilhelms-Universität Bonn, Germany (A.P.)
| | - Stephanie Blodow
- From the Walter Brendel Centre of Experimental Medicine, University Hospital, Biomedical Center, Munich, Germany (K.P., H.M., S.B., H.S., K.M.S., J.Q., H.B., L.I.T., U.P., P.K.); Protein Analysis Unit, Biomedical Center, Munich, Germany (A.S., A.I.); DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Germany (K.P., H.M., S.B., H.S., K.M.S., J.Q., H.B., U.P., P.K.); Munich Cluster for Systems Neurology (SyNergY), Germany (A.I., U.P.); and Institute of Pharmacology and Toxicology, Rheinische Friedrich-Wilhelms-Universität Bonn, Germany (A.P.)
| | - Holger Schneider
- From the Walter Brendel Centre of Experimental Medicine, University Hospital, Biomedical Center, Munich, Germany (K.P., H.M., S.B., H.S., K.M.S., J.Q., H.B., L.I.T., U.P., P.K.); Protein Analysis Unit, Biomedical Center, Munich, Germany (A.S., A.I.); DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Germany (K.P., H.M., S.B., H.S., K.M.S., J.Q., H.B., U.P., P.K.); Munich Cluster for Systems Neurology (SyNergY), Germany (A.I., U.P.); and Institute of Pharmacology and Toxicology, Rheinische Friedrich-Wilhelms-Universität Bonn, Germany (A.P.)
| | - Kai Michael Schubert
- From the Walter Brendel Centre of Experimental Medicine, University Hospital, Biomedical Center, Munich, Germany (K.P., H.M., S.B., H.S., K.M.S., J.Q., H.B., L.I.T., U.P., P.K.); Protein Analysis Unit, Biomedical Center, Munich, Germany (A.S., A.I.); DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Germany (K.P., H.M., S.B., H.S., K.M.S., J.Q., H.B., U.P., P.K.); Munich Cluster for Systems Neurology (SyNergY), Germany (A.I., U.P.); and Institute of Pharmacology and Toxicology, Rheinische Friedrich-Wilhelms-Universität Bonn, Germany (A.P.)
| | - Jiehua Qiu
- From the Walter Brendel Centre of Experimental Medicine, University Hospital, Biomedical Center, Munich, Germany (K.P., H.M., S.B., H.S., K.M.S., J.Q., H.B., L.I.T., U.P., P.K.); Protein Analysis Unit, Biomedical Center, Munich, Germany (A.S., A.I.); DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Germany (K.P., H.M., S.B., H.S., K.M.S., J.Q., H.B., U.P., P.K.); Munich Cluster for Systems Neurology (SyNergY), Germany (A.I., U.P.); and Institute of Pharmacology and Toxicology, Rheinische Friedrich-Wilhelms-Universität Bonn, Germany (A.P.)
| | - Andreas Schmidt
- From the Walter Brendel Centre of Experimental Medicine, University Hospital, Biomedical Center, Munich, Germany (K.P., H.M., S.B., H.S., K.M.S., J.Q., H.B., L.I.T., U.P., P.K.); Protein Analysis Unit, Biomedical Center, Munich, Germany (A.S., A.I.); DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Germany (K.P., H.M., S.B., H.S., K.M.S., J.Q., H.B., U.P., P.K.); Munich Cluster for Systems Neurology (SyNergY), Germany (A.I., U.P.); and Institute of Pharmacology and Toxicology, Rheinische Friedrich-Wilhelms-Universität Bonn, Germany (A.P.)
| | - Axel Imhof
- From the Walter Brendel Centre of Experimental Medicine, University Hospital, Biomedical Center, Munich, Germany (K.P., H.M., S.B., H.S., K.M.S., J.Q., H.B., L.I.T., U.P., P.K.); Protein Analysis Unit, Biomedical Center, Munich, Germany (A.S., A.I.); DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Germany (K.P., H.M., S.B., H.S., K.M.S., J.Q., H.B., U.P., P.K.); Munich Cluster for Systems Neurology (SyNergY), Germany (A.I., U.P.); and Institute of Pharmacology and Toxicology, Rheinische Friedrich-Wilhelms-Universität Bonn, Germany (A.P.)
| | - Heike Beck
- From the Walter Brendel Centre of Experimental Medicine, University Hospital, Biomedical Center, Munich, Germany (K.P., H.M., S.B., H.S., K.M.S., J.Q., H.B., L.I.T., U.P., P.K.); Protein Analysis Unit, Biomedical Center, Munich, Germany (A.S., A.I.); DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Germany (K.P., H.M., S.B., H.S., K.M.S., J.Q., H.B., U.P., P.K.); Munich Cluster for Systems Neurology (SyNergY), Germany (A.I., U.P.); and Institute of Pharmacology and Toxicology, Rheinische Friedrich-Wilhelms-Universität Bonn, Germany (A.P.)
| | - Laurentia Irina Tanase
- From the Walter Brendel Centre of Experimental Medicine, University Hospital, Biomedical Center, Munich, Germany (K.P., H.M., S.B., H.S., K.M.S., J.Q., H.B., L.I.T., U.P., P.K.); Protein Analysis Unit, Biomedical Center, Munich, Germany (A.S., A.I.); DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Germany (K.P., H.M., S.B., H.S., K.M.S., J.Q., H.B., U.P., P.K.); Munich Cluster for Systems Neurology (SyNergY), Germany (A.I., U.P.); and Institute of Pharmacology and Toxicology, Rheinische Friedrich-Wilhelms-Universität Bonn, Germany (A.P.)
| | - Alexander Pfeifer
- From the Walter Brendel Centre of Experimental Medicine, University Hospital, Biomedical Center, Munich, Germany (K.P., H.M., S.B., H.S., K.M.S., J.Q., H.B., L.I.T., U.P., P.K.); Protein Analysis Unit, Biomedical Center, Munich, Germany (A.S., A.I.); DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Germany (K.P., H.M., S.B., H.S., K.M.S., J.Q., H.B., U.P., P.K.); Munich Cluster for Systems Neurology (SyNergY), Germany (A.I., U.P.); and Institute of Pharmacology and Toxicology, Rheinische Friedrich-Wilhelms-Universität Bonn, Germany (A.P.)
| | - Ulrich Pohl
- From the Walter Brendel Centre of Experimental Medicine, University Hospital, Biomedical Center, Munich, Germany (K.P., H.M., S.B., H.S., K.M.S., J.Q., H.B., L.I.T., U.P., P.K.); Protein Analysis Unit, Biomedical Center, Munich, Germany (A.S., A.I.); DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Germany (K.P., H.M., S.B., H.S., K.M.S., J.Q., H.B., U.P., P.K.); Munich Cluster for Systems Neurology (SyNergY), Germany (A.I., U.P.); and Institute of Pharmacology and Toxicology, Rheinische Friedrich-Wilhelms-Universität Bonn, Germany (A.P.).
| | - Petra Kameritsch
- From the Walter Brendel Centre of Experimental Medicine, University Hospital, Biomedical Center, Munich, Germany (K.P., H.M., S.B., H.S., K.M.S., J.Q., H.B., L.I.T., U.P., P.K.); Protein Analysis Unit, Biomedical Center, Munich, Germany (A.S., A.I.); DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Germany (K.P., H.M., S.B., H.S., K.M.S., J.Q., H.B., U.P., P.K.); Munich Cluster for Systems Neurology (SyNergY), Germany (A.I., U.P.); and Institute of Pharmacology and Toxicology, Rheinische Friedrich-Wilhelms-Universität Bonn, Germany (A.P.)
| |
Collapse
|
2
|
Schubert KM, Qiu J, Blodow S, Wiedenmann M, Lubomirov LT, Pfitzer G, Pohl U, Schneider H. The AMP-Related Kinase (AMPK) Induces Ca
2+
-Independent Dilation of Resistance Arteries by Interfering With Actin Filament Formation. Circ Res 2017; 121:149-161. [DOI: 10.1161/circresaha.116.309962] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/12/2016] [Revised: 05/23/2017] [Accepted: 06/06/2017] [Indexed: 12/13/2022]
Abstract
Rationale:
Decreasing Ca
2+
sensitivity of vascular smooth muscle (VSM) allows for vasodilation without lowering of cytosolic Ca
2+
. This may be particularly important in states requiring maintained dilation, such as hypoxia. AMP-related kinase (AMPK) is an important cellular energy sensor in VSM. Regulation of Ca
2+
sensitivity usually is attributed to myosin light chain phosphatase activity, but findings in non-VSM identified changes in the actin cytoskeleton. The potential role of AMPK in this setting is widely unknown.
Objective:
To assess the influence of AMPK on the actin cytoskeleton in VSM of resistance arteries with regard to potential Ca
2+
desensitization of VSM contractile apparatus.
Methods and Results:
AMPK induced a slowly developing dilation at unchanged cytosolic Ca
2+
levels in potassium chloride–constricted intact arteries isolated from mouse mesenteric tissue. This dilation was not associated with changes in phosphorylation of myosin light chain or of myosin light chain phosphatase regulatory subunit. Using ultracentrifugation and confocal microscopy, we found that AMPK induced depolymerization of F-actin (filamentous actin). Imaging of arteries from LifeAct mice showed F-actin rarefaction in the midcellular portion of VSM. Immunoblotting revealed that this was associated with activation of the actin severing factor cofilin. Coimmunoprecipitation experiments indicated that AMPK leads to the liberation of cofilin from 14-3-3 protein.
Conclusions:
AMPK induces actin depolymerization, which reduces vascular tone and the response to vasoconstrictors. Our findings demonstrate a new role of AMPK in the control of actin cytoskeletal dynamics, potentially allowing for long-term dilation of microvessels without substantial changes in cytosolic Ca
2+
.
Collapse
Affiliation(s)
- Kai Michael Schubert
- From the Walter Brendel Centre of Experimental Medicine, Biomedical Center of LMU, Ludwig Maximilian University of Munich, Germany (K.M.S., J.Q., S.B., M.W., U.P., H.S.); Munich Cluster for Systems Neurology (SyNergy), Germany (K.M.S., S.B., U.P., H.S.); Deutsches Zentrum für Herz- Kreislauf-Forschung (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany (K.M.S., S.B., U.P., H.S.); and Institute of Vegetative Physiology, University of Cologne, Germany (L.T
| | - Jiehua Qiu
- From the Walter Brendel Centre of Experimental Medicine, Biomedical Center of LMU, Ludwig Maximilian University of Munich, Germany (K.M.S., J.Q., S.B., M.W., U.P., H.S.); Munich Cluster for Systems Neurology (SyNergy), Germany (K.M.S., S.B., U.P., H.S.); Deutsches Zentrum für Herz- Kreislauf-Forschung (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany (K.M.S., S.B., U.P., H.S.); and Institute of Vegetative Physiology, University of Cologne, Germany (L.T
| | - Stephanie Blodow
- From the Walter Brendel Centre of Experimental Medicine, Biomedical Center of LMU, Ludwig Maximilian University of Munich, Germany (K.M.S., J.Q., S.B., M.W., U.P., H.S.); Munich Cluster for Systems Neurology (SyNergy), Germany (K.M.S., S.B., U.P., H.S.); Deutsches Zentrum für Herz- Kreislauf-Forschung (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany (K.M.S., S.B., U.P., H.S.); and Institute of Vegetative Physiology, University of Cologne, Germany (L.T
| | - Margarethe Wiedenmann
- From the Walter Brendel Centre of Experimental Medicine, Biomedical Center of LMU, Ludwig Maximilian University of Munich, Germany (K.M.S., J.Q., S.B., M.W., U.P., H.S.); Munich Cluster for Systems Neurology (SyNergy), Germany (K.M.S., S.B., U.P., H.S.); Deutsches Zentrum für Herz- Kreislauf-Forschung (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany (K.M.S., S.B., U.P., H.S.); and Institute of Vegetative Physiology, University of Cologne, Germany (L.T
| | - Lubomir T. Lubomirov
- From the Walter Brendel Centre of Experimental Medicine, Biomedical Center of LMU, Ludwig Maximilian University of Munich, Germany (K.M.S., J.Q., S.B., M.W., U.P., H.S.); Munich Cluster for Systems Neurology (SyNergy), Germany (K.M.S., S.B., U.P., H.S.); Deutsches Zentrum für Herz- Kreislauf-Forschung (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany (K.M.S., S.B., U.P., H.S.); and Institute of Vegetative Physiology, University of Cologne, Germany (L.T
| | - Gabriele Pfitzer
- From the Walter Brendel Centre of Experimental Medicine, Biomedical Center of LMU, Ludwig Maximilian University of Munich, Germany (K.M.S., J.Q., S.B., M.W., U.P., H.S.); Munich Cluster for Systems Neurology (SyNergy), Germany (K.M.S., S.B., U.P., H.S.); Deutsches Zentrum für Herz- Kreislauf-Forschung (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany (K.M.S., S.B., U.P., H.S.); and Institute of Vegetative Physiology, University of Cologne, Germany (L.T
| | - Ulrich Pohl
- From the Walter Brendel Centre of Experimental Medicine, Biomedical Center of LMU, Ludwig Maximilian University of Munich, Germany (K.M.S., J.Q., S.B., M.W., U.P., H.S.); Munich Cluster for Systems Neurology (SyNergy), Germany (K.M.S., S.B., U.P., H.S.); Deutsches Zentrum für Herz- Kreislauf-Forschung (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany (K.M.S., S.B., U.P., H.S.); and Institute of Vegetative Physiology, University of Cologne, Germany (L.T
| | - Holger Schneider
- From the Walter Brendel Centre of Experimental Medicine, Biomedical Center of LMU, Ludwig Maximilian University of Munich, Germany (K.M.S., J.Q., S.B., M.W., U.P., H.S.); Munich Cluster for Systems Neurology (SyNergy), Germany (K.M.S., S.B., U.P., H.S.); Deutsches Zentrum für Herz- Kreislauf-Forschung (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany (K.M.S., S.B., U.P., H.S.); and Institute of Vegetative Physiology, University of Cologne, Germany (L.T
| |
Collapse
|
3
|
Schneider H, Schubert KM, Blodow S, Kreutz CP, Erdogmus S, Wiedenmann M, Qiu J, Fey T, Ruth P, Lubomirov LT, Pfitzer G, Mederos y Schnitzler M, Hardie DG, Gudermann T, Pohl U. AMPK Dilates Resistance Arteries via Activation of SERCA and BK
Ca
Channels in Smooth Muscle. Hypertension 2015; 66:108-16. [DOI: 10.1161/hypertensionaha.115.05514] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2015] [Accepted: 04/30/2015] [Indexed: 01/12/2023]
Affiliation(s)
- Holger Schneider
- From the Walter-Brendel Centre of Experimental Medicine and Biomedical Center (H.S., K.M.S., S.B., C.-P.K., M.W., J.Q., T.F., U.P.) and Walther Straub Institute, Pharmacology (S.E., M.M.y.S., T.G.), Ludwig-Maximilians Universität München, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (H.S., K.M.S., S.B., U.P.); DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany (H.S., K.M.S., S.B., T.F., M.M.y.S., T.G., U.P.)
| | - Kai Michael Schubert
- From the Walter-Brendel Centre of Experimental Medicine and Biomedical Center (H.S., K.M.S., S.B., C.-P.K., M.W., J.Q., T.F., U.P.) and Walther Straub Institute, Pharmacology (S.E., M.M.y.S., T.G.), Ludwig-Maximilians Universität München, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (H.S., K.M.S., S.B., U.P.); DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany (H.S., K.M.S., S.B., T.F., M.M.y.S., T.G., U.P.)
| | - Stephanie Blodow
- From the Walter-Brendel Centre of Experimental Medicine and Biomedical Center (H.S., K.M.S., S.B., C.-P.K., M.W., J.Q., T.F., U.P.) and Walther Straub Institute, Pharmacology (S.E., M.M.y.S., T.G.), Ludwig-Maximilians Universität München, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (H.S., K.M.S., S.B., U.P.); DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany (H.S., K.M.S., S.B., T.F., M.M.y.S., T.G., U.P.)
| | - Claus-Peter Kreutz
- From the Walter-Brendel Centre of Experimental Medicine and Biomedical Center (H.S., K.M.S., S.B., C.-P.K., M.W., J.Q., T.F., U.P.) and Walther Straub Institute, Pharmacology (S.E., M.M.y.S., T.G.), Ludwig-Maximilians Universität München, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (H.S., K.M.S., S.B., U.P.); DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany (H.S., K.M.S., S.B., T.F., M.M.y.S., T.G., U.P.)
| | - Serap Erdogmus
- From the Walter-Brendel Centre of Experimental Medicine and Biomedical Center (H.S., K.M.S., S.B., C.-P.K., M.W., J.Q., T.F., U.P.) and Walther Straub Institute, Pharmacology (S.E., M.M.y.S., T.G.), Ludwig-Maximilians Universität München, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (H.S., K.M.S., S.B., U.P.); DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany (H.S., K.M.S., S.B., T.F., M.M.y.S., T.G., U.P.)
| | - Margarethe Wiedenmann
- From the Walter-Brendel Centre of Experimental Medicine and Biomedical Center (H.S., K.M.S., S.B., C.-P.K., M.W., J.Q., T.F., U.P.) and Walther Straub Institute, Pharmacology (S.E., M.M.y.S., T.G.), Ludwig-Maximilians Universität München, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (H.S., K.M.S., S.B., U.P.); DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany (H.S., K.M.S., S.B., T.F., M.M.y.S., T.G., U.P.)
| | - Jiehua Qiu
- From the Walter-Brendel Centre of Experimental Medicine and Biomedical Center (H.S., K.M.S., S.B., C.-P.K., M.W., J.Q., T.F., U.P.) and Walther Straub Institute, Pharmacology (S.E., M.M.y.S., T.G.), Ludwig-Maximilians Universität München, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (H.S., K.M.S., S.B., U.P.); DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany (H.S., K.M.S., S.B., T.F., M.M.y.S., T.G., U.P.)
| | - Theres Fey
- From the Walter-Brendel Centre of Experimental Medicine and Biomedical Center (H.S., K.M.S., S.B., C.-P.K., M.W., J.Q., T.F., U.P.) and Walther Straub Institute, Pharmacology (S.E., M.M.y.S., T.G.), Ludwig-Maximilians Universität München, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (H.S., K.M.S., S.B., U.P.); DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany (H.S., K.M.S., S.B., T.F., M.M.y.S., T.G., U.P.)
| | - Peter Ruth
- From the Walter-Brendel Centre of Experimental Medicine and Biomedical Center (H.S., K.M.S., S.B., C.-P.K., M.W., J.Q., T.F., U.P.) and Walther Straub Institute, Pharmacology (S.E., M.M.y.S., T.G.), Ludwig-Maximilians Universität München, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (H.S., K.M.S., S.B., U.P.); DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany (H.S., K.M.S., S.B., T.F., M.M.y.S., T.G., U.P.)
| | - Lubomir T. Lubomirov
- From the Walter-Brendel Centre of Experimental Medicine and Biomedical Center (H.S., K.M.S., S.B., C.-P.K., M.W., J.Q., T.F., U.P.) and Walther Straub Institute, Pharmacology (S.E., M.M.y.S., T.G.), Ludwig-Maximilians Universität München, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (H.S., K.M.S., S.B., U.P.); DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany (H.S., K.M.S., S.B., T.F., M.M.y.S., T.G., U.P.)
| | - Gabriele Pfitzer
- From the Walter-Brendel Centre of Experimental Medicine and Biomedical Center (H.S., K.M.S., S.B., C.-P.K., M.W., J.Q., T.F., U.P.) and Walther Straub Institute, Pharmacology (S.E., M.M.y.S., T.G.), Ludwig-Maximilians Universität München, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (H.S., K.M.S., S.B., U.P.); DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany (H.S., K.M.S., S.B., T.F., M.M.y.S., T.G., U.P.)
| | - Michael Mederos y Schnitzler
- From the Walter-Brendel Centre of Experimental Medicine and Biomedical Center (H.S., K.M.S., S.B., C.-P.K., M.W., J.Q., T.F., U.P.) and Walther Straub Institute, Pharmacology (S.E., M.M.y.S., T.G.), Ludwig-Maximilians Universität München, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (H.S., K.M.S., S.B., U.P.); DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany (H.S., K.M.S., S.B., T.F., M.M.y.S., T.G., U.P.)
| | - D. Grahame Hardie
- From the Walter-Brendel Centre of Experimental Medicine and Biomedical Center (H.S., K.M.S., S.B., C.-P.K., M.W., J.Q., T.F., U.P.) and Walther Straub Institute, Pharmacology (S.E., M.M.y.S., T.G.), Ludwig-Maximilians Universität München, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (H.S., K.M.S., S.B., U.P.); DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany (H.S., K.M.S., S.B., T.F., M.M.y.S., T.G., U.P.)
| | - Thomas Gudermann
- From the Walter-Brendel Centre of Experimental Medicine and Biomedical Center (H.S., K.M.S., S.B., C.-P.K., M.W., J.Q., T.F., U.P.) and Walther Straub Institute, Pharmacology (S.E., M.M.y.S., T.G.), Ludwig-Maximilians Universität München, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (H.S., K.M.S., S.B., U.P.); DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany (H.S., K.M.S., S.B., T.F., M.M.y.S., T.G., U.P.)
| | - Ulrich Pohl
- From the Walter-Brendel Centre of Experimental Medicine and Biomedical Center (H.S., K.M.S., S.B., C.-P.K., M.W., J.Q., T.F., U.P.) and Walther Straub Institute, Pharmacology (S.E., M.M.y.S., T.G.), Ludwig-Maximilians Universität München, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (H.S., K.M.S., S.B., U.P.); DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany (H.S., K.M.S., S.B., T.F., M.M.y.S., T.G., U.P.)
| |
Collapse
|
4
|
Storch U, Blodow S, Gudermann T, Mederos Y Schnitzler M. Cysteinyl leukotriene 1 receptors as novel mechanosensors mediating myogenic tone together with angiotensin II type 1 receptors-brief report. Arterioscler Thromb Vasc Biol 2014; 35:121-6. [PMID: 25395620 DOI: 10.1161/atvbaha.114.304844] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
OBJECTIVE Myogenic vasoconstriction is mediated by vascular smooth muscle cells of resistance arteries sensing mechanical stretch. Angiotensin II AT1 receptors and in particular AT1BRs in murine vascular smooth muscle cells have been characterized as mechanosensors that cannot fully account for myogenic vasoconstriction observed. Therefore, we aimed at uncovering novel vascular mechanosensors by expression profiling and functional characterization of candidate proteins. APPROACH AND RESULTS Analyzing myogenic tone of isolated murine mesenteric arteries of AT1A and AT1B receptor double gene-deficient (AT1A/1B (-/-)) mice ex vivo, we observed a decreased myogenic tone at high intraluminal pressures and an unexpected hyper-reactivity at low intraluminal pressures because of upregulation of cysteinyl leukotriene 1 receptors (CysLT1Rs). Pharmacological blockade of CysLT1Rs with pranlukast significantly reduced myogenic tone not only in AT1A/1B (-/-) but also in wild-type arteries. In wild-type arteries, additional blockade of angiotensin II AT1 receptors with candesartan resulted in an additive reduction of myogenic tone. Furthermore, calcium imaging experiments were performed with fura-2-loaded human embryonic kidney 293 cells overexpressing CysLT1Rs and with isolated mesenteric vascular smooth muscle cells. Hypo-osmotically induced membrane stretch provoked calcium transients that were significantly reduced by pranlukast. Incubations of isolated mesenteric vascular smooth muscle cells with the 5-lipoxygenase inhibitor zileuton had no effect. Furthermore, the Gq/11-protein inhibitor YM 254890 profoundly reduced myogenic tone to the same extent as induced by the application of pranlukast plus candesartan. CONCLUSIONS Here, we identify a novel, hitherto unappreciated role of CysLT1Rs in vascular regulation. We identified CysLT1Rs as novel mechanosensors in the vasculature involved in myogenic vasoconstriction. Moreover, our findings suggest that myogenic tone is determined by AT1 and CysLT1 receptors acting together as mechanosensors via Gq/11-protein activation.
Collapse
Affiliation(s)
- Ursula Storch
- From the Walther Straub Institute of Pharmacology and Toxicology (U.S., S.B., T.G., M.MyS.), Ludwig Maximilians University of Munich, Munich, Germany; and DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance (T.G., M.MyS.), Munich, Germany
| | - Stephanie Blodow
- From the Walther Straub Institute of Pharmacology and Toxicology (U.S., S.B., T.G., M.MyS.), Ludwig Maximilians University of Munich, Munich, Germany; and DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance (T.G., M.MyS.), Munich, Germany
| | - Thomas Gudermann
- From the Walther Straub Institute of Pharmacology and Toxicology (U.S., S.B., T.G., M.MyS.), Ludwig Maximilians University of Munich, Munich, Germany; and DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance (T.G., M.MyS.), Munich, Germany.
| | - Michael Mederos Y Schnitzler
- From the Walther Straub Institute of Pharmacology and Toxicology (U.S., S.B., T.G., M.MyS.), Ludwig Maximilians University of Munich, Munich, Germany; and DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance (T.G., M.MyS.), Munich, Germany.
| |
Collapse
|
5
|
Blodow S, Schneider H, Storch U, Wizemann R, Forst AL, Gudermann T, Mederos y Schnitzler M. Novel role of mechanosensitive AT1B receptors in myogenic vasoconstriction. Pflugers Arch 2013; 466:1343-53. [PMID: 24101294 DOI: 10.1007/s00424-013-1372-3] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2013] [Revised: 09/26/2013] [Accepted: 09/27/2013] [Indexed: 01/15/2023]
Abstract
Myogenic vasoconstriction is an inherent property of vascular smooth muscle cells (VSMCs) of resistance arteries harboring ill-defined mechanosensing and mechanotransducing elements. G protein-coupled receptors (GPCRs) are discussed as mechanosensors in VSMCs. In this study, we sought to identify and characterize the role and impact of GPCRs on myogenic vasoconstriction. Thus, we analyzed mRNA expression levels of GPCRs in resistance versus preceding conduit arteries revealing a significant enrichment of several GPCRs in resistance vessels. Selective pharmacological blockade of the highly expressed GPCRs in isolated murine mesenteric arteries ex vivo decreased myogenic vasoconstriction. In particular, candesartan and losartan most prominently suppressed myogenic tone, suggesting that AT1 receptors play a central role in myogenic vasoconstriction. Analyzing angiotensinogen(-/-) mice, a relevant contribution of locally produced angiotensin II to myogenic tone could be excluded. Investigation of AT1A (-/-) and AT1B (-/-) murine mesenteric arteries revealed that AT1B, but not AT1A, receptors are key components of myogenic regulation. This notion was supported by examining fura-2-loaded isolated AT1A (-/-) and AT1B (-/-) VSMCs. Our results indicate that in VSMCs, AT1B receptors are more mechanosensitive than AT1A receptors even at comparable receptor expression levels. Furthermore, we demonstrate that the mechanosensitivity of GPCRs is agonist-independent and positively correlates with receptor expression levels.
Collapse
Affiliation(s)
- Stephanie Blodow
- Walther-Straub-Institute of Pharmacology and Toxicology, Ludwig Maximilians University of Munich, Goethestr. 33, 80336, Munich, Germany
| | | | | | | | | | | | | |
Collapse
|